New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection

Future Medicinal Chemistry

Volumn 7, Issue 15, 2015, Pages 1961-1969

  Buendia, Izaskun ^a,b   Navarro, Elisa ^a,b   Michalska, Patrycja ^a,b   Gameiro, Isabel ^a,b   Egea, Javier ^a,b   Abril, Sheila ^a,b   López, Alicia ^a   González Lafuente, Laura ^a,b   López, Manuela G ^a,b   León, Rafael ^a,b  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID DERIVATIVE; CINNAMIC ACID; FREE RADICAL; MELATONIN; N ACETYLSEROTONIN; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; CINNAMIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CELL VIABILITY; CELLS; DEGENERATIVE DISEASE; DRUG TARGETING; GENE INDUCTION; HYBRID; IN VITRO STUDY; LIVER TOXICITY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TOXICOLOGY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; NEURODEGENERATIVE DISEASES; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTIOXIDANTS; CINNAMATES; HUMANS; MELATONIN; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84947073264     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.99     Document Type: Article

References (40)

1. Ross CA, Poirier MA. Opinion: what is the role of protein aggregation in neurodegeneration?. Nat. Rev. Mol. Cell Biol. 6(11), 891-898 (2005
2. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113), 787-795 (2006
3. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 10(Suppl.), S18-S25 (2004
4. Dasuri K, Zhang L, Keller JN. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic. Biol. Med. 62, 170-185 (2013
5. Forman HJ, Davies KJ, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic. Biol. Med. 66, 24-35 (2014
6. Ramsey CP, Glass CA, Montgomery MB et al. Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 66(1), 75-85 (2007
7. Kanninen K, Malm TM, Jyrkkanen HK et al. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol. Cell Neurosci. 39(3), 302-313 (2008
8. Innamorato NG, Jazwa A, Rojo AI et al. Different susceptibility to the Parkinson s toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PloS ONE 5(7), e11838 (2010
9. Lee DH, Stangel M, Gold R, Linker RA. The fumaric acid ester BG-12: A new option in MS therapy. Expert Rev. Neurother. 13(8), 951-958 (2013
10. Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, Talalay P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl Acad. Sci. USA 98(6), 3404-3409 (2001
11. Mauriz JL, Collado PS, Veneroso C, Reiter RJ, Gonzalez-Gallego J. A review of the molecular aspects of melatonin s anti-inflammatory actions: recent insights and new perspectives. J. Pineal Res. 54(1), 1-14 (2013
12. Wu YH, Feenstra MG, Zhou JN et al. Molecular changes underlying reduced pineal melatonin levels in alzheimer disease: alterations in preclinical and clinical stages. J. Clin. Endocrinol. Metab. 88(12), 5898-5906 (2003
13. Parada E, Buendia I, Leon R et al. Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptor modulation and HO-1 overexpression. J. Pineal Res. 56(2), 204-212 (2014
14. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 42(1), 28-42 (2007
15. Vriend J, Reiter RJ. The Keap1-Nrf2-Antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. Mol. Cell Endocrinol. 401, 213-220 (2015
16. Pandi-Perumal SR, Bahammam AS, Brown GM et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox. Res. 23(3), 267-300 (2013
17. Egea J, Buendia I, Parada E et al. Melatonin-sulforaphane hybrid ITH12674 induces neuroprotection in oxidative stress conditions by a drug-prodrug mechanism of action. Br. J. Pharmacol. 172(7), 1807-1821 (2015
18. Neises B, Steglich W. Simple method for the esterification of carboxylic acids. Angew. Chem. Int. Ed. Engl. 17(7), 522-524 (1978
19. Wang XJ, Hayes JD, Wolf CR. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of Nrf2 by cancer chemotherapeutic agents. Cancer Res. 66(22), 10983-10994 (2006
20. Satoh T, Mckercher SR, Lipton SA. Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic. Biol. Med. 65, 645-657 (2013
21. Wright JS, Johnson ER, Dilabio GA. Predicting the activity of phenolic antioxidants: theoretical method, analysis of substituent effects, and application to major families of antioxidants. J. Am. Chem. Soc. 123(6), 1173-1183 (2001
22. Davalos A, Gomez-Cordoves C, Bartolome B. Extending applicability of the oxygen radical absorbance capacity (ORACfluorescein) assay. J. Agric. Food Chem. 52(1), 48-54 (2004
23. Wolfler A, Abuja PM, Schauenstein K, Liebmann PM. N-Acetylserotonin is a better extra-And intracellular antioxidant than melatonin. FEBS Lett. 449(2-3), 206-210 (1999
24. Cavalli A, Bolognesi ML, Capsoni S et al. A small molecule targeting the multifactorial nature of Alzheimer s disease. Angew. Chem. Int. Ed. Engl. 46(20), 3689-3692 (2007
25. Romero A, Egea J, Garcia AG, Lopez MG. Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. J. Pineal Res. 49(2), 141-148 (2010
26. Kamat PK, Rai S, Nath C. Okadaic acid induced neurotoxicity: an emerging tool to study Alzheimer s disease pathology. Neurotoxicology 37, 163-172 (2013
27. Perez M, Hernandez F, Gomez-Ramos A, Smith M, Perry G, Avila J. Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur. J. Biochem. 269(5), 1484-1489 (2002
28. Edelstein J, Rockwell P. Okadaic acid induces Akt hyperphosphorylation and an oxidative stress-mediated cell death in serum starved SK-N-SH human neuroblastoma cells that are augmented by rapamycin. Neurosci. Lett. 531(2), 74-79 (2012
29. Kamat PK, Rai S, Swarnkar S, Shukla R, Nath C. Mechanism of synapse redox stress in Okadaic acid (ICV) induced memory impairment: role of NMDA receptor. Neurochem. Int. 76, 32-41 (2014
30. Zhang Z, Simpkins JW. An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Res. 1359, 233-246 (2010
31. Arias C, Sharma N, Davies P, Shafit-Zagardo B. Okadaic acid induces early changes in microtubule-Associated protein 2 and tau phosphorylation prior to neurodegeneration in cultured cortical neurons. J. Neurochem. 61(2), 673-682 (1993
32. Egea J, Rosa AO, Sobrado M, Gandia L, Lopez MG, Garcia AG. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in alpha7 nicotinic receptor knockout mice. Neuroscience 145(3), 866-872 (2007
33. Chen H, Yoshioka H, Kim GS et al. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid. Redox. Signal. 14(8), 1505-1517 (2011
34. Chan K, Jensen N, O'brien PJ. Structure-Activity relationships for thiol reactivity and rat or human hepatocyte toxicity induced by substituted p-benzoquinone compounds. J. Appl. Toxicol. 28(5), 608-620 (2008
35. Day BJ. Antioxidant therapeutics: Pandora s box. Free Radic. Biol. Med. 66, 58-64 (2014
36. Wang XJ, Hayes JD, Higgins LG, Wolf CR, Dinkova-Kostova AT. Activation of the NRF2 signaling pathway by copper-mediated redox cycling of para-And orthohydroquinones. Chem. Biol. 17(1), 75-85 (2010
37. Leon R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer s disease. Med. Res. Rev. 33(1), 139-189 (2013
38. Carnevale D, De Simone R, Minghetti L. Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol. Disord. Drug Targets 6(6), 388-397 (2007
39. Tan DX, Manchester LC, Terron MP, Flores LJ, Tamura H, Reiter RJ. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J. Pineal Res. 43(4), 317-320 (2007
40. Dufour M, Yan C, Siegel D et al. Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition. Chembiochem 12(8), 1203-1208 (2011